Nephrology

Phosphate Binders song

Listen to the preview here. The full song is free on YouTube.

Phosphate Binders

Full song on YouTube ↗

Key points in this song10

Phosphate binders are used in chronic kidney disease (CKD) to treat hyperphosphatemia, which drives secondary hyperparathyroidism, renal osteodystrophy, and vascular calcification.
Calcium-based binders (calcium carbonate, calcium acetate) are first-line but are avoided in hypercalcemia, vascular calcification, or adynamic bone disease due to risk of calcium overload.
Sevelamer (a non-calcium, non-aluminum polymer) binds phosphate in the gut without raising serum calcium and also lowers LDL cholesterol — a unique secondary benefit.
Lanthanum carbonate is a non-calcium, non-aluminum binder chewed with meals; it is effective but carries theoretical concerns about long-term tissue accumulation.
Aluminum hydroxide is the most potent phosphate binder but is restricted to short-term use due to risk of aluminum toxicity — causing osteomalacia, encephalopathy, and microcytic anemia.
All phosphate binders must be taken with meals to bind dietary phosphate before intestinal absorption — timing is critical for efficacy.
In dialysis patients, sevelamer and lanthanum are preferred over calcium-based binders to avoid worsening vascular and soft-tissue calcification.
Sucroferric oxyhydroxide (iron-based binder) and ferric citrate are newer options that bind phosphate and can improve iron stores simultaneously in dialysis patients.
Dietary phosphate restriction (< 800–1000 mg/day) is always initiated alongside binder therapy — binders alone are insufficient without limiting phosphate intake.
Target serum phosphate in CKD stages 3–5 and dialysis patients is 3.5–5.5 mg/dL per KDIGO guidelines; uncontrolled hyperphosphatemia is an independent risk factor for cardiovascular mortality.